Analysts Expect Ultragenyx Pharmaceutical Inc (RARE) Will Post Earnings of -$1.95 Per Share

Analysts predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will announce earnings per share of ($1.95) for the current quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.80) and the lowest estimate coming in at ($2.11). Ultragenyx Pharmaceutical reported earnings per share of ($1.87) in the same quarter last year, which suggests a negative year over year growth rate of 4.3%. The company is scheduled to issue its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($4.40) per share for the current financial year, with EPS estimates ranging from ($4.92) to ($4.02). For the next fiscal year, analysts forecast that the business will report earnings of ($6.53) per share, with EPS estimates ranging from ($7.80) to ($3.33). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($2.08) by $1.02. The company had revenue of $12.79 million during the quarter, compared to analyst estimates of $5.63 million. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. During the same period in the previous year, the firm earned ($1.72) earnings per share.

RARE has been the subject of several recent analyst reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 29th. Canaccord Genuity lifted their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, August 3rd. Robert W. Baird reaffirmed a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 3rd. BidaskClub lowered shares of Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Finally, JMP Securities reaffirmed a “buy” rating and set a $94.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Sunday, September 2nd. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $85.53.

NASDAQ RARE traded up $0.56 on Monday, hitting $74.73. 518,500 shares of the stock were exchanged, compared to its average volume of 520,149. The firm has a market capitalization of $3.83 billion, a price-to-earnings ratio of -9.99 and a beta of 1.95. Ultragenyx Pharmaceutical has a 52-week low of $41.67 and a 52-week high of $90.98.

In related news, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total value of $603,469.00. Following the completion of the sale, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at $5,118,497.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director William Aliski sold 3,750 shares of the company’s stock in a transaction dated Wednesday, August 8th. The stock was sold at an average price of $76.66, for a total transaction of $287,475.00. Following the completion of the sale, the director now directly owns 72,610 shares of the company’s stock, valued at $5,566,282.60. The disclosure for this sale can be found here. Insiders have sold 15,450 shares of company stock valued at $1,283,594 over the last three months. Insiders own 8.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Xact Kapitalforvaltning AB raised its holdings in Ultragenyx Pharmaceutical by 10.6% in the second quarter. Xact Kapitalforvaltning AB now owns 7,323 shares of the biopharmaceutical company’s stock worth $563,000 after purchasing an additional 700 shares in the last quarter. Profund Advisors LLC raised its holdings in Ultragenyx Pharmaceutical by 5.6% in the first quarter. Profund Advisors LLC now owns 16,653 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 889 shares in the last quarter. GAM Holding AG raised its holdings in Ultragenyx Pharmaceutical by 2.0% in the second quarter. GAM Holding AG now owns 50,700 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 1,000 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its holdings in Ultragenyx Pharmaceutical by 7.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 15,187 shares of the biopharmaceutical company’s stock worth $1,167,000 after purchasing an additional 1,037 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in Ultragenyx Pharmaceutical by 4.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 26,319 shares of the biopharmaceutical company’s stock worth $2,023,000 after purchasing an additional 1,100 shares in the last quarter. 96.09% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

See Also: How to Invest in Marijuana Stocks

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply